Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of uproleselan plus chemotherapy vs chemotherapy alone in acute myeloid leukemia
2018-001076-38Phase 3Terminated
- Sponsor
- GlycoMimetics, Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of uproleselan in acute myeloid leukemia (AML), sponsored by GlycoMimetics, Inc.. Started Oct 2018; status: terminated.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-001076-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001076-38.